Navigation Links
NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
Date:10/18/2010

i>.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements about NeurogesX' plans to submit a supplemental NDA to the FDA and the timing of such submission; expected data to be included in such submission; additional market reach of expanding the Qutenza label to include treatment of pain associated with HIV-AN and the ability to use the U.S. sales force and other relationships to facilitate commercialization of Qutenza in the potential new indication. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Sara Pellegrino (investor
'/>"/>


SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at J.P. Morgan Health Care Conference
2. NeurogesX to Present at Piper Jaffray Health Care Conference
3. NeurogesX Reports Third Quarter 2009 Results
4. NeurogesX to Present at Two November Conferences
5. NeurogesX to Present at UBS Global Life Sciences Conference
6. NeurogesX to Present at Upcoming Fall Conferences
7. NeurogesX Appoints New Board Director and Audit Committee Chairman
8. NeurogesX Reports Second Quarter 2009 Results
9. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
10. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
11. NeurogesX Added to Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... February 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... secrets lawsuit against Genewiz Inc. in excess of $10 ... utilized GenScript’s trade secrets, and that it improperly hired ... entered an order denying motions for judgment notwithstanding the ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... ORANGE COUNTY, Calif., Sept. 10 Beckman,Coulter, Inc. (NYSE: ... products that simplify, automate, and innovate complex biomedical tests,announces ... accordingly., (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ... Tuesday, October 28, 2008. Q3 ...
... growing number of US clinics, CHICAGO, IL, ... the,world,s first commercially available bionic hand, today revealed ... National Assembly of the American,Orthotic and Prosthetic Association ... company,s RACE Team and Partner Program are designed ...
... 10 A top 5 bio-pharmaceutical,company has ... multiple therapeutic areas within its global,Translational Medicine ... company decided to adopt the Labmatrix,technology after ... pilot by end,users and the research informatics ...
Cached Biology Technology:Beckman Coulter Investor Events Second Half of 2008 2Touch Bionics unveils innovative partner and reimbursement programs at AOPA 2Touch Bionics unveils innovative partner and reimbursement programs at AOPA 3
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... companies could economically convert their operations to wood boilers ... forestry researchers. The conversion to wood-powered burners would make ... in areas that have access to large timber resources ... professor of wood operations, Penn State. Wood is ...
... University biology professor Chris Martine has discovered and described ... City. Martine, who named the plant Solanum cowiei , ... . Martine described the plant as "gender bending," ... by producing pollen. "What they,re really doing is ...
... Professor Keon Jae Lee and Professor ... Science and Engineering at KAIST has developed the biotemplated ... Nature has its own capabilities to spontaneously ... as shells, sea sponges, and bone minerals. For instance, ...
Cached Biology News:Companies could make the switch to wood power 2Unlikely collaboration leads to discovery of 'gender-bending' plant 2Unlikely collaboration leads to discovery of 'gender-bending' plant 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... A.D. Smith et.al. (1997) ... entries on current biochemistry & ... than 17,000 headwords. Entries give ... the processes in which they ...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
Biology Products: